Eli Lilly | LLY - Current Liabilities


Eli Lilly reported $47.74B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Abbott USD 18.38B 1.88B Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Baxter International USD 3.59B 102M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 75.51M 56.82M Jun/2026
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
Eli Lilly USD 47.74B 11.11B Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
J&J USD 54.9B 2.82B Jun/2026
Medtronic USD 11.8B 141M Jun/2026
Merck USD 27.73B 786M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novartis USD 31.37B 4.1B Mar/2026
Novo Nordisk DKK 239.08B 13.92B Jun/2026
Perrigo USD 1.05B 57.2M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Phibro Animal Health USD 316.47M 34.6M Jun/2026
Prestige Brands USD 153.81M 32.88M Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sanofi EUR 30.01B 1.66B Mar/2026
United Therapeutics USD 607.8M 8.7M Jun/2026
Zoetis USD 2.06B 8M Jun/2026